Published in:
01-07-2007 | Correspondence
Cost-Utility Analysis in China: Differences and Difficulties Compared with Developed Countries
Authors:
Liu Bao Peng, Chong Qing Tan, Xiao Min Wan, Wei Cui
Published in:
PharmacoEconomics
|
Issue 7/2007
Login to get access
Excerpt
Many countries have adopted cost-utility analysis to evaluate the costs and outcomes associated with new drugs. In China, the National Center for Pharmacoeconomics (NCPE) places great emphasis on the use of cost-utility analysis. However, some of the patients and medical personnel in China do not presently consider cost-utility analysis to be important, and pharmacoeconomic studies in China are still difficult to conduct. In particular, it is difficult to evaluate the quality of life of patients in China; hence, the use of cost-utility analysis is limited. Indeed, to date we know of only a few published cost-utility analyses[
1‐
3] of a treatment from a Chinese perspective. …
